key: cord-0709720-zb034sbv authors: Franco-Munoz, C.; Alvarez-Diaz, D. A.; Laiton-Donato, K.; Wiesner, M.; Escandon, P.; Usme-Ciro, J. A.; Franco-Sierra, N. D.; Florez-Sanchez, A. C.; Gomez-Rangel, S.; Rodriguez Calderon, L. D.; Barbosa Ramirez, J.; Ospitia Baez, E.; Walteros, D. M.; Ospina Martinez, M. L.; Mercado-Reyes, M. title: Substitutions in Spike and Nucleocapsid proteins of SARS-CoV-2 circulating in Colombia date: 2020-06-04 journal: nan DOI: 10.1101/2020.06.02.20120782 sha: 27341589828323667b33c6a7af73922c87130786 doc_id: 709720 cord_uid: zb034sbv Introduction: SARS-CoV-2 is a new member of the genus Betacoronavirus, responsible for the COVID-19 pandemics. The virus crossed the species barrier and established in the human population due to its ability to exploit the ACE receptor for virus entry, which is present and abundant in several tissues, including the lung and respiratory tract, gastrointestinal tract and hearth. Virus interaction with the cellular receptor is mediated by the surface protein, known as Spike. Another structural protein of major importance in the Nucleocapsid, directly interacting with the viral RNA to form the ribonucleocapsid, considered a multifunctional protein, and being the target of the most molecular diagnostics assays. Objective: To describe the frequency of substitutions in spike and nucleocapsid proteins of SARS-CoV-2 circulating in Colombia and evaluate the frequency of these substitutions in SARS-CoV-2 sequences from other countries of South America. Materials and methods: Samples of 43 patients were included for viral RNA detection by real-time RT-PCR using the Charite-Berlin protocol for the amplification of the SARS-CoV-2 E and RdRp genes. Genome sequences were obtained through the Oxford Nanopore and Illumina MiSeq technologies, following the artic.network "nCoV-2019 sequencing protocol". Available genomes were consulted from GISAID, GenBank, and Genome sequence archive (GSA) and a total of 371 genomes sequences from South America were included. The genome sequences were aligned with the Muscle tool using the MEGA X software. Substitution matrices of the Colombian sequences respect to the reference genome (NC_045512) at the nucleotide and amino acid levels were generated for the spike and nucleocapsid gene. Results: substitution D614G in the amino acid sequence of spike protein was found in 86.7% of the Colombian sequences; substitutions G181V and D936Y in 2.3%, respectively. Five substitutions were found in the nucleocapsid protein, with substitution R203K and G204R being the most frequent (13.95 %) in Colombia. The substitutions D614G in Spike and R203K-G204R in nucleocapsid have a frequency of 83% and 28% respectively in sequences from South America. Conclusion: Non-synonymous substitutions were found in the spike and nucleocapsid proteins in Colombian genomes, the most frequent being D614G in Spike and R203K-G204R in nucleocapsid. These substitutions are frequent in the genomes reported for other South American countries. It is necessary to continue with genomic surveillance of the changes in Spike and Nucleocapsid proteins during the SARS-CoV-2 pandemic in Colombia and South America, even more considering that these proteins are the most commonly used antigen in serological tests. Colombia is the reference lab and health authority of the national network of 133 laboratories and in cases of public health emergency or those in which scientific 134 research for public health purposes as required. The INS is authorized to use the 135 biological material for research purposes, without informed consent, which includes 136 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 4, 2020. . the anonymous disclosure of results. This study was performed following the 137 ethical standards of the Declaration of Helsinki 1964 and its later amendments. 138 The information used for this study comes from secondary sources of data that 139 were previously anonymized and do protect patient data. 140 Nasopharyngeal swab samples from patients with suspected SARS-CoV-2 142 infection were processed for RNA extraction using the automated MagNA Pure LC 143 nucleic acid extraction system (Roche Diagnostics GmbH, Mannheim, Germany) 144 and viral RNA detection was performed by real-time RT-PCR using the SuperScript 145 III Platinum One-Step Quantitative RT-qPCR kit (Thermo Fisher Scientific, 146 Waltham, MA, USA), following the Charité-Berlin protocol (Corman et al., 2020) for 147 the amplification of the SARS-CoV-2 E (betacoronavirus screening assay) and 148 RdRp (SARS-CoV-2 confirmatory assay) genes. 149 NGS of SARS-CoV-2 from 43 patients was performed using the amplicon-based 151 Illumina and Nanopore sequencing approaches, ARTIC network protocol (Quick, 152 2020a). Following cDNA synthesis with SuperScript IV reverse transcriptase 153 (Thermo Fisher Scientific, Waltham, MA, USA) and random hexamers (Thermo 154 Fisher Scientific, Waltham, MA, USA), a set of 400-bp tiling amplicons across the 155 whole genome of SARS-CoV-2 were generated using the primer schemes nCoV-156 2019/V3 (Quick, 2020a) . 157 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Three amino acid changes were observed in the spike protein of Colombian SARS-177 CoV-2 sequences compared to the reference sequence (NC_045512.2). Spike 178 protein substitution D614G is present in 81% (35/43) of the sequences reported in 179 this study. The following substitutions were also found in lower frequency: G181V 180 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 4, 2020. America. The R191C substitution in the nucleocapsid protein was observed in two 227 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 4, 2020. In the analysis of the nonsynonymous substitutions in the Spike protein of 233 Recombinant proteins or synthetic peptides from SARS-CoV-2 derived from the 296 reported genomic information is a well-explored alternative for the production of 297 antigens to be used in serological tests, considering that the production of total 298 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 4, 2020. . viral antigen implies biosafety challenges and the need for a BSL3 laboratory. 299 Taking into account that Spike and Nucleocapsid are the major immunogenic 300 proteins of SARS and MERS coronavirus and the first choice for producing 301 recombinant antigens (Yan, Chang, & Wang, 2020) , it is essential to continue with 302 the evolutionary monitoring of genes included in the original designs of serological 303 tests, because amino acid changes can affect the conformational structure and 304 physical-chemical properties of the proteins. Considering that reduced 305 immunogenicity in Spike protein is associated with the D614G amino acid change, 306 it could also be having impact in serosurveillance studies in countries where the 307 subtype G614 is prevalent, such as Spain, where a seroprevalence of 5% was 308 registered (MSCBS, 2020). CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 4, 2020. . https://doi.org/10.1101/2020.06.02.20120782 doi: medRxiv preprint Molecular analysis of 339 several in-house rRT-PCR protocols for SARS-CoV-2 detection in the context of 340 genetic variability of the virus in Colombia. medRxiv Reporting Two SARS-CoV-2 Strains Based on A Unique 343 Trinucleotide-Bloc Mutation and Their Potential Pathogenic Difference SARS CoV 2 viral spike G614 mutation 346 exhibits higher case fatality rate Global Spread of SARS-CoV-2 Subtype with Spike Protein 349 Mutation D614G is Shaped by Human Genomic Variations that Regulate 350 Expression of TMPRSS2 and MX1 Genes Distinct Viral Clades of SARS CoV 2: Implications for Modeling of 352 Viral Spread Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. 355 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 356 communicable disease bulletin The spike protein of 359 SARS-CoV-a target for vaccine and therapeutic development MUSCLE: multiple sequence alignment with high accuracy and high 362 throughput Loss of Epitopes from SARS-Cov-2 Proteins for Non-364 synonymous Mutations: A Potential Global Threat Temporal 366 dynamics in viral shedding and transmissibility of COVID-19 Coronavirus (COVID -2019) en Colombia Understanding Antibody Testing for 371 COVID-19 A Novel 373 Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their 374 Antigenicity and Immunogenicity? Vaccines Spike mutation pipeline reveals the emergence of a more 377 transmissible form of SARS-CoV-2. bioRxiv MEGA7: molecular evolutionary genetics 379 analysis version 7.0 for bigger datasets Serological Approaches for 382 COVID-19: Epidemiologic Perspective on Surveillance and Control Bayesian phylodynamic inference on the temporal 385 evolution and global transmission of SARS-CoV-2 The global emergences of multiple SARS-CoV-2 sub-strains: 392 Digital annotations for human behaviors may assist automated retracing of 393 symptomatic features and origins nCoV-2019 sequencing protocol Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-398 coronavirus 2 On the origin and 402 continuing evolution of SARS-CoV-2 WHO Director-General's opening remarks at the media briefing on 405 COVID-19 -11 Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 409 2019-nCoV in humans Laboratory testing of SARS CoV, MERS CoV, 413 and SARS CoV 2 (2019 nCoV): Current status, challenges, and 414 countermeasures Severe acute respiratory syndrome coronavirus group-specific open 417 reading frames encode nonessential functions for replication in cell cultures and 418 mice Figure 1. Spatiotemporal distribution of the most frequently substitutions in Spike 441 and Nucleocapsid of SARS-CoV-2. A. Distribution of subtypes D614 and G614 of spike 442 protein in SARS-CoV-2 genomes reported as of May 19th, 2020 in Colombia South American countries; in red, variant D614 and in green, variant G614. B. Distribution 444 of subtypes D614 and G614 of spike protein in SARS-CoV-2 genomes in Colombia, according with the sample collection date, variant 446 D614 and in green, variant G614. C. Distribution of subtypes R203/G204 and K203/R204 447 of nucleocapsid protein in SARS-CoV-2 genomes reported as of Colombia and other South American countries, in red, variant R203/G204 and in blue, 449 variant K203/R204. D. Distribution of subtypes R203/G204 and K203/R204 of 450 nucleocapsid protein in SARS-CoV-2 genomes reported between according with the sample collection date in Colombia, in red